Novo Nordisk A/S (NVO) vs Takeda Pharmaceutical (TAK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Takeda Pharmaceutical (TAK) has outperformed Novo Nordisk A/S (NVO) over the past year, gaining 52.2% versus a loss of 20.6%. Over five years, TAK leads with a +60.9% price change compared with -30.1% for NVO. Novo Nordisk A/S is the larger company by market cap ($166.69 billion vs $69.55 billion), about 2.4 times the size.
On valuation, Novo Nordisk A/S trades at a lower forward P/E (10.8x vs 41.1x for Takeda Pharmaceutical). Takeda Pharmaceutical offers the higher dividend yield (927.88% vs 30.94%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NVO | TAK |
|---|---|---|
| Share price | $37.82 | $21.77 |
| Market cap | $166.69B | $69.55B |
| 1-day change | -2.70% | +1.68% |
| YTD return | -25.67% | +39.64% |
| 1-year return | -20.60% | +52.24% |
| 5-year return | -30.07% | +60.90% |
| P/E ratio (TTM) | 9.55 | 311.00 |
| Forward P/E | 10.77 | 41.08 |
| EPS (TTM) | $3.96 | $0.07 |
| Dividend yield | 30.94% | 927.88% |
| Annual dividend | $11.70 | $202.00 |
| 52-week high | $64.16 | $22.07 |
| 52-week low | $35.12 | $14.16 |
| Distance from 52-week high | -41.05% | -1.36% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +20.28% | +12.68% |
| Average volume | 12.59M | 2.73M |
| Shares outstanding | 3.33B | 3.19B |
| Employees | 68,794 | 47,029 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Novo Nordisk A/S is about 2.4 times larger than Takeda Pharmaceutical by market value ($166.69B vs $69.55B).
- TAK has outperformed NVO by 72.8 percentage points over the past year.
- Takeda Pharmaceutical trades at a higher earnings multiple (311.0x vs 9.6x trailing P/E).
- Takeda Pharmaceutical offers a meaningfully higher dividend yield (927.88% vs 30.94%).
About Novo Nordisk A/S
NVO stock →Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 68,794 employees
About Takeda Pharmaceutical
TAK stock →Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience.
Health Care · Biotechnology: Pharmaceutical Preparations · 47,029 employees
NVO vs TAK FAQ
Which is bigger, Novo Nordisk A/S or Takeda Pharmaceutical?
Novo Nordisk A/S (NVO) is larger, with a market capitalization of $166.69B compared with $69.55B for Takeda Pharmaceutical (TAK).
Which stock has performed better over the past year, NVO or TAK?
TAK returned +52.24% over the past 12 months, compared with -20.60% for NVO (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, NVO or TAK?
NVO has the lower trailing P/E at 9.6, versus 311.0 for TAK. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Novo Nordisk A/S or Takeda Pharmaceutical?
Takeda Pharmaceutical has the higher yield at 927.88%, compared with 30.94% for Novo Nordisk A/S.
Are Novo Nordisk A/S and Takeda Pharmaceutical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.